

# James A Smith

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8442102/publications.pdf>

Version: 2024-02-01

16  
papers

324  
citations

1040018

9  
h-index

940516

16  
g-index

23  
all docs

23  
docs citations

23  
times ranked

511  
citing authors

#	ARTICLE	IF	CITATIONS
1	Biosecurity in an age of open science. PLoS Biology, 2022, 20, e3001600.	5.6	11
2	The case for an academic discipline of medical device science. EFORT Open Reviews, 2021, 6, 160-163.	4.1	0
3	Growing backlog of planned surgery due to covid-19. BMJ, The, 2021, 372, n339.	6.0	74
4	Improving transparency and reproducibility of patent landscapes: the Reporting Items for Patent Landscapes (RIPL) statement and other considerations. World Patent Information, 2020, 62, 101985.	1.7	5
5	Industry ties and evidence in public comments on the FDA framework for modifications to artificial intelligence/machine learning-based medical devices: a cross sectional study. BMJ Open, 2020, 10, e039969.	1.9	9
6	Bioprocess decision support tool for scalable manufacture of extracellular vesicles. Biotechnology and Bioengineering, 2019, 116, 307-319.	3.3	28
7	Potential lifetime quality of life benefits of choroideremia gene therapy: projections from a clinically informed decision model. Eye, 2019, 33, 1215-1223.	2.1	9
8	The Reporting Items for Patent Landscapes statement. Nature Biotechnology, 2018, 36, 1043-1047.	17.5	19
9	Evidence of insufficient quality of reporting in patent landscapes in the life sciences. Nature Biotechnology, 2017, 35, 210-214.	17.5	12
10	Conditional Approval Pathways: The “Special” Case of Global Regenerative Medicine Regulation. Rejuvenation Research, 2017, 20, 1-3.	1.8	11
11	A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics. Frontiers in Genetics, 2016, 6, 357.	2.3	10
12	Cell assisted lipotransfer in breast augmentation and reconstruction: A systematic review of safety, efficacy, use of patient reported outcomes and study quality. JPRAS Open, 2016, 10, 5-20.	0.9	21
13	Establishing good authentication practice (GAP) in secondary care to protect against falsified medicines and improve patient safety. European Journal of Hospital Pharmacy, 2016, 23, 118-120.	1.1	13
14	The magnitude and temporal changes of response in the placebo arm of surgical randomized controlled trials: a systematic review and meta-analysis. Trials, 2016, 17, 589.	1.6	34
15	Generating iPSCs: Translating Cell Reprogramming Science into Scalable and Robust Biomanufacturing Strategies. Cell Stem Cell, 2015, 16, 13-17.	11.1	60
16	21 <sup>st</sup> Century Cures Act: An Act of Cure or Diagnosis?. Rejuvenation Research, 2015, 18, 295-298.	1.8	5